Precigen says FDA grants platform technology designation for AdenoVerse immunotherapy platform
PGEN•FDA grants designation for AdenoVerse platform
- FDA granted platform technology designation to Precigen’s AdenoVerse immunotherapy platform.
- Status could speed development of new AdenoVerse-based programs by leveraging PAPZIMEOS manufacturing and preclinical data in future filings.
- AdenoVerse underpins PAPZIMEOS, an FDA-approved treatment for recurrent respiratory papillomatosis cleared in August 2025.
Related News
Xencor, Inc. <XNCR.O>: BofA Global Research raises price objective to $26 from $20
XNCR•
Armata says AP-SA02 genetic diversity may boost killing of some Staph aureus isolates in clinical testing
ARMP•
